Newer therapeutic vistas for Antiglaucoma medicines

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 28, Issue 2, 2011, Pages 165-202

  Kaur, Indu Pal ^a   Singh, Harinder ^a   Kakkar, Shilpa ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Antiglaucoma agents; Lipophilicity; Nanoparticles; Novel drug delivery system; Ocular; RNA interference

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ANTIGLAUCOMA AGENT; APRACLONIDINE; ATROPINE; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; CARTEOLOL; COLLAGEN; DENDRIMER; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; LEVOBUNOLOL; LIPOSOME; METHAZOLAMIDE; METOPROLOL; NANOPARTICLE; NCX 125; PILOCARPINE; SMALL INTERFERING RNA; TIMOLET GFS; TIMOLOL; TIMOLOL MALEATE; TIMOSAN; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ANXIETY; ARTICLE; BLEPHARITIS; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; CARDIOTOXICITY; CATARACT; CILIARY MUSCLE SPASM; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CORNEA EDEMA; CORNEA EROSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRY EYE; EPIPHORA; EYE BURNING; EYE DISEASE; EYE IRRITATION; EYE STINGING; EYE TOXICITY; EYELASH; EYELID RETRACTION; FATIGUE; FOLLICULAR CONJUNCTIVITIS; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART BLOCK; HEART PALPITATION; HUMAN; HYDROGEN BOND; HYDROPHILICITY; HYPEREMIA; HYPERTRICHOSIS; HYPOTENSION; INSOMNIA; INTRAOCULAR HYPERTENSION; IRIS DISEASE; IRIS HYPERPIGMENTATION; IRIS PIGMENTATION; KERATITIS; LACRIMATION; LUNG TOXICITY; MALAISE; METABOLIC ACIDOSIS; MICROEMULSION; MIOSIS; MONOTHERAPY; MUSCLE SPASM; MYDRIASIS; MYOPIA; NAUSEA; NONHUMAN; OPEN ANGLE GLAUCOMA; PARTICLE SIZE; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; POLYURIA; RETINA DETACHMENT; SALIVATION; SIDE EFFECT; STOMACH UPSET; SUPERFICIAL PUNCTATE KERATITIS; SWEATING; TASTE; UNSPECIFIED SIDE EFFECT; VISCOSITY; VOMITING; XEROSTOMIA;

EID: 79958837233     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i2.20     Document Type: Article

References (246)

1. Marquis RE, Whitson JT. Management of glaucoma; focus on pharmacological therapy. Drugs Aging. 2005;22:1-21.
2. Hoyng PFJ, Van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs. 2000;59: 411-434.
3. Brao-Osuna I, Checa P, Herrero-Vanrell R. New therapeutic systems of newroprotectors agents in the treatment of glaucoma. Arch Soc Esp Ofthalmol. 2007;82:191-194.
4. Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin North Am. 2005;18: 585-596.
5. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish II RK, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary openangle glaucoma. Arch Ophthalmol. 2002;120:714-720.
6. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish II RK, Wilson MR, Gordon MO. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
7. Jonas JB, Martus P, Horn FK, Jünemann A, Korth M, Budde WM. Predictive factors of the optic nerve head for development or progression of glaucomatous visual field loss. Invest Ophthalmol Vis Sci. 2004;45:2613-2618.
8. Kroese M, Burton H. Primary open angle glaucoma. the need for a consensus case definition. J Epidemiol Community Health. 2003;57, 752-754.
9. Koliopoulos JX. Time as a risk factor for primary open angle glaucoma: a scientific and philosophical approach. Ann Ophthalmol. 1996;28:354-356.
10. Martus P, Stroux A, Budde WM, Mardin CY, Korth M, Jonas JB. Predictive factors for progressive optic nerve damage in various types of chronic openangle glaucoma. Am J Ophthalmol. 2005;139:999-1009.
11. Clark AF, Wang WH, McNatt L. RNAi inhibition of serum amyloid a for treatment of glaucoma. United States Patent Application 20110054008. Published on 03/03/2011.
12. Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15:132-135.
13. Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea J Pharm Sci. 1987;76:583-586.
14. Loftsson T, Stefansson E. Effect of cyclodextrins on topical drug delivery to the eye. Drug Devel Ind Pharm. 1997;23:473-481.
15. Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev. 1995;16: 39-43.
16. Chrai SS, Patton TF, Mehta A, Robinson JR. Lacrimal and instilled fluid dynamics in the rabbit eye. J Pharm Sci. 1973;62:1112-121.
17. Gangrade NK, Gaddipati NB, Ganesan MG, Reddy IK: Topical ophthalmic formulations: basic considerations. In: Reddy IK, editors. Ocular therapeutics and drug delivery. Lancaster, UK: Technomic; 1996. pp. 377-403.
18. Loftsson T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36: 59-79.
19. Washington N, Washington C, Wilson CG. Physiological pharmaceutics: barriers to drug Absorption. London: Taylor & Francis; 2001.
20. Shell JW. Ophthalmic drug delivery systems. Drug Dev Res. 1985;6:245-261.
21. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Delivery Rev. 1995a;16:61-73.
22. Chang SC, Lee VHL. Nasal and conjunctival contributions to the systemic absorption of topical ti molol in the pigmented rabbit: implications in the design of strategics to maximize the ratio of ocular to systemic absorption. J Ocul Pharmacol. 1987;3:159-169.
23. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol. 1993;37:435-456.
24. Kreuter J. Particulates (nanoparticles and microparticles). In: Mitra AK, editors. Ophthalmic drug delivery systems. New York: Marcel Dekker; 1993. pp. 275-285.
25. Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002;27:353-370.
26. Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systemsrecent advances. Prog Retin Eye Res. 1998;17:33-58.
27. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21:15-34.
28. Lesar TS. Glaucoma. In: DiPiro JT and Talbert RL, editors. Pharmacotherapy; a pathophysiologic approach. Stamford, CT: Appleton & Lange; 1999. pp. 1466-1478.
29. Khaw PT, Shah P, Elkington AR. Glaucoma-2: treatment. Br Med J. 2004;328:156-158.
30. Schuman JS. Short-and long-term safety of glaucoma drugs. Expert Opin Drug Saf. 2002;1:181-194.
31. Lee VHL, Robinson JR. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J Pharm Sci. 1979;66:673-684.
32. Bundgaard H, Falch E, Larsen C, Mikkelson TJ. Pilocarpine prodrugs I. synthesis, physicochemical properties and kinetics of lactonization of pilocarpic acid esters. J Pharm Sci. 1986;75:36-43.
33. Bundgaard H, Falch E, Larsen C, Mosher G, Mikkelson TJ. Pilocarpine prodrugs II. synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. J Pharm Sci. 1986;75:775-783.
34. Druzgala P, Winwood D, Drewniak-Deyrup M, Smith S, Bodor N, Kaminski JJ. New water-soluble pilocarpine derivatives with enhanced and sustained muscarinic activity. Pharm Res. 1992;9:372-377.
35. Mosher GL. Theoretical and experimental evaluation of pilocarpine prodrugs for ocular delivery. PhD thesis, University of Kansas, 1986.
36. Järvinen, T.; Suhonen, P.; Urtti, A.; Peura, P. O,O'-(1,4-Xylylene) Bispilocarpic Acid Esters as New Potential Double Prodrugs of Pilocarpine for Improved Ocular Delivery. II. Physicochemical Properties, Stability, Solubility and Enzymatic Hydrolysis. Int. J. Pharm. 1991;75:259-269.
37. Suhonen P, Jairvinen T, Lehmussaari K, Reunamaiki T, Urtti A. Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharm Res. 1995;12:529-533.
38. Ellingson CM, Schoenwald RD, Barfknecht CF, Rao CS, Laban SL. Rapid toxicological model for use in assessing ocular drugs. Biopharm Drug Disposit. 1992;14:417-436.
39. Lee IP. A possible mechanism of ellipticine-induced hemolysis. J Pharmac Exp Ther. 1976;196: 525-535.
40. Lewis RW, McCall JC, Bothman PA, Trebilcock R. A comparison of two cytotoxicity tests for predicting the ocular irritancy of surfactants. Toxic in Vitro. 1994;8:867-869.
41. Luxnat M, Galla HJ. Partition of chlorpromazine into lipid bilayer membranes: The effect of membrane structure and composition. Biochim Biophys Acta. 1986;856:274-282.
42. Saarinen-Savolainen P, Jarvinen T, Suhonen P, Urtti A. Amphiphilic properties of pilocarpine prodrugs. Int J Pharm 1996;133:171-178.
43. Lee VHL, Takemoto KA, Iimoto DS. Precorneal factors influencing the ocular distribution of topically applied liposomal inulin. Curr Eye Res. 1984;3:585-591.
44. Benita S, Plenecassagne JD, Cave G, Drouin D, Dong P, Sincholle D. Pilocarpine hydrochloride liposomes: characterization in vitro and preliminary evaluation in vivo in rabbit eye. J Microencapsulation. 1984;1:203-216.
45. Szulc J, Woyczikowski B, De Laval W. Effect of pilocarpine hydrochloride liposomes on the intraocular pressure of the rabbit eye pupil. Farm Pol. 1988;44:462-465.
46. Shaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982;22: 220-227.
47. Taniguchi K, Yamamoto Y, Itakura K, Miichi H, Hayashi S. Assessment of ocular irritability of liposome preparations. J Pharmacobiodyn. 1988;11:607-611.
48. Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HClin normal and glaucomatous rabbits. Int J Pharm. 2000;198:29-38.
49. Ticho U, Blumenthal M, Zonis S, Gal A, Blank I, Mazor ZW. A clinical trial with Piloplex-a new long-acting pilocarpine compound: preliminary report. Ann Ophthalmol. 1979;4:555-561.
50. Lee VHL, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol Ther. 1986;2:67-108.
51. Harmia T, Speiser P, Kreuter J, Boye T, Gurny R, Kubis A. Enhancement of the miotic response of rabbits with pilocarpine-loaded poly-butylcyanoacrylate nanoparticles. Int J Pharm. 1986;33:187-193.
52. Diepold R, Kreuter J, Himber J, Gurny R, Lee VHL, Robinson JR, Saettone MF, Chnaudigel OE. Comparison of different models for the testing of pilocarpine eye-drops using conventional eye-drops and a novel depot formulation (nanoparticles). Graefes Arch Clin Exp Ophthalmol. 1989;227:188-193.
53. Marchal-Heussler L, Maincent P, Hoffman M, Spittler J, Couvreur P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. Int J Pharm. 1990;58:115-122.
54. Zimmer AK, Chetoni P, Saettone MF, Zerbe H, Kreuter J. Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. co-administration with bioadhesive and viscous polymers. J Control Release. 1995b;33:31-46.
55. Ding S. Recent developments in ophthalmic drug delivery. Pharm Sci Technol. 1998;1:328-335.
56. Kao HJ, Lin HR, Lo YL, Yu SP. Characterization of pilocarpine-loaded chitosan/carbopol nanoparticles. J Pharm Pharmacol. 2006;58:179-186.
57. Hasse A, Keipert S. Development and characterization of microemulsions for ocular application. Eur J Pharm Biopharm. 1997;43:179-183.
58. Benita S, Levy MY. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J Pharm Sci. 1993;82:1069-1079.
59. Klang SH, Frucht-Pery J, Hoffman A, Benita S. Physicochemical characterization and acute toxicity evaluation of a positively charged submicron emulsion vehicle. J Pharm Pharmacol. 1994;46:986-993.
60. Kushnick H, Liebmann JM, Ritch R. Systemic pilocarpine toxicity from ocusert leakage. Arch Ophthalmol. 1996;114:1432.
61. Vasantha R, Sehgal PK, Rao PK. Collagen ophthalmic inserts for pilocarpine drug delivery system. Int J Pharm. 1988;47:95-102.
62. Kaufman HE, Steinemann TL, Lehman E, Thompson HW, Varnell ED, Jacob-Labarre JT, Gebhardt BM. Collagen-based drug delivery and artificial tears. J Ocul Pharmacol. 1994;10:17-27.
63. Bochot A, Fattal E, Gulik A, Couarraze G, Couvreur P. Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides. Pharm Res. 1998;15:1364-1369.
64. Ibrahim H, Bindschaedler C, Doelker E, Buri P, Gurny R. Concept and development of ophthalmic pseudo-lattices triggered by pH. Int J Pharm. 1991; 77:211-219
65. Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite R. A novel, ion-activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57:163-168.
66. Desai SD, Blanchard J: Ocular drug formulation and delivery. In: Swarbrick J and Boylan J, editors. Encyclopedia of pharmaceuticaltechnology, Vol. 11. New York: Marcel Dekker; 1995. pp. 43-75.
67. Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for oculardelivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102:23-38.
68. Bhadra D, Bhadra S, Jain S, Jain NK. A pegylated dendritic nanaparticulate carrier of fluorouracil. Int J Pharm. 2003;257:111-124.
69. Milhem OM, Myles C, McKeown NB, Attwood D, D'Emanuelle A. Polyamidoamine StarburstR dendrimers as solubility enhancers. Int J Pharm. 2000;197:239-241.
70. Ooya T, Lee J, Park K. Effects of ethylene glycol based graft, star-shaped, and dendritic polymers on solubilization and controlled release of placlitaxel. J Control Release. 2003;93 121-127.
71. Beezer AE, King ASH, Martin IK, Mitchel JC, Twyman LJ, Wain CF. Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM dendrimers. Tetrahedron. 2003;59:3873-3880.
72. Devarakonda B, Hill RA, De Villiers MM. The effect of PAMAM dendrimer generation size and surface functional groups on the aqueous solubility of nifedipine. Int J Pharm. 2004;284:133-140.
73. Liu M, Kono K, Frechet JMJ. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release. 2000;65:121-131.
74. Sorensen SJ, Abel SR. Comparison of the ocular beta blockers. Ann Pharmacother. 1996;30:43-54.
75. Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmol. 1978;85:268-275.
76. Kaback MB, Podos SM, Harbin Jr TS, Mandell A, Becker B. The effects of dipivalyl epinephrine on the eye. Am J Ophthalmol. 1976; 81:768-772.
77. Schmetterer L, Strenn K, Findl O, Breiteneder H, Graselli U, Agneter E, Eichler HG, Wolzt M. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin Pharmacol Ther. 1997;61:583-595.
78. Wang YL, Hayashi M, Yablonski ME, Toris CB. Effects of multiple dosing of epinephrine on aqueous humor dynamics in human eyes. J Ocul Pharmacol Ther. 2002;18:53-63.
79. Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic preparations of acetazolamide. Int J Pharm. 2000;199:119-127.
80. Kaur IP, Smitha R, Aggarwal D, Kapil M. Acetazolamide: future perspective in topical glaucoma therapeutics. Int J Pharm. 2002;248:1-14.
81. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmol. 1998;105:1952-1959.
82. Tsukamoto H, Noma H, Matsuvama S, Ikeda H, Mishima HK. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a betablocker in patients with glaucoma. J Ocul Pharmacol Ther. 2005;21:170-173.
83. Drake M. New medical therapies for glaucoma. Int Ophthalmol Clin. 1996;36:53-60.
84. Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol. 1997;42:137-151.
85. Loftsson T, Frioriksdottir H, Stefansson E, Thorisdottir S, Guomundsson O, Sigthorsson T. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol. 1994;46:503-504.
86. Loftsson T, Stefansson E, Kristensson JK, Fridriksdottir H, Sverrisson T, Gudmondsdottir G, Thorisdottir S. Topically effective acetazolamide eye-drop solution in man. Pharm Sci. 1996;6:277-279.
87. Loftsson T, Brewster ME, Drendorf H, Bodor N. 2-Hydroxypropyl-β-cyclodextrins: properties and usage in pharmaceutical formulations. Ztg Wiss. 1991;1:175-180.
88. Javitt JC, Javitt NB, McDonnell P. Topical compositions for the eye comprising a β-cyclodextrin derivative and a carbonic anhydrase inhibitor. WO 94/15582.1994.
89. Loftsson T, Olafsdottir BJ, Bodor N. The effects of cyclodextrins on transdermal delivery of drugs. Eur J Pharm Biopharm. 1991;37:30-33.
90. Szejtli J. Cyclodextrin technology. The Netherlands. 1988;39:188-192.
91. Kaur IP, Kapil M, Smitha R, Aggarwal D. Development of topically effective formulations of acetazolamide using HP-β-CD-polymer co-complexes. Curr Drug Del. 2004;1:65-72.
92. Loftsson T, Fridriksdottir H, Gudmondsdottir TK. The effect of water-soluble polymers on aqueous solubility of drugs. Int J Pharm. 1996;127:293-296.
93. El-Gazayerly ON, Hikal AH. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm. 1997;158:121-127.
94. Friedman Z, Allen RC, Raph SM. Topical acetazolamide and methazolamide delivered by contact lenses. Arch Ophthalmol. 1985;103:963-966.
95. Kaur IP, Mitra AK, Aggarwal D. Development of a vesicular system for effective ocular delivery of acetazolamide a comprehensive approach and successful venture. J Drug Del Sci Tech. 2007;17: 33-41.
96. Tous SS, Nasser KAE. Acetazolamide topical formulation and ocular effect. STP Pharm Sci. 1992;2:125-131.
97. Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005;306:71-82.
98. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004a;269:1-14.
99. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172:33-70.
100. Carafa M, Santicci E, Alhaique F, Coviello T, Murtas E, Riccieri FM, Lucania G, Torrisi MR. Preparation and properties of new unilamellar non-ionic surfactant vesicles. Int J Pharm. 1998;160:51-59.
101. Carafa M, Santicci E, Lucania G. Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm. 2002;231:21-32.
102. Duarte AR, Roy C, Vega-González A, C.M. D, P. S-P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int J Pharm. 2007;6:132-139.
103. Konowal A, Morrison JC, Brown SVL, Cooke DL, Maguire LJ, Verdier DV, Fraunfelder FT, Dennis RF, Epstein RJ. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403-406.
104. Maren TH, Haywood JR, Chapman SK, Zimmerman TJ. The pharmacology of methazolamide in relation to the treatment of glaucoma. Invest Ophthalmol Vis Sci. 1977;16:730-742.
105. Sugrue ME, Mallogra P, Schwam H, Baldwin JJ, Ponticello GS. A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res. 1990;9:607-615.
106. Sigurdsson HH, Stefansson E, Gudmundsdottir E, Eysteinsson T, Thorsteinsdottir M, Loftsson T. Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. J Control Release. 2005;102:255-262.
107. Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Surv Ophthalmol. 2000;44:141-145.
108. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10:808-819.
109. Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention. J Control Release. 2006;111:145-52.
110. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000;45:89-121.
111. Bucolo C, Maltese A, Maugeri F, Busa B, Puglisi G, Pignatello R. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J Pharm Pharmacol. 2004;56:841-846.
112. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23:3247-3255.
113. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136:2-13.
114. Papadimitriou S, Bikiaris D, Avgoustakis K, Karavas E, Georgarakis M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym. 2008;73:44-54.
115. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic inhibitors. Prog Retin Eye Res 2000;19 87-112.
116. Katz L. Brimonidine-purite Study Groups 1 and 2: twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;1:119-126.
117. Stewart WC, Sharpe ED, Harbin Jr TS. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol. 2000;129:723-727.
118. Javitt J, Goldberg I. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. J Glaucoma. 2000;9:298-408.
119. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41:S9-S18.
120. Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther. 2007;23:481-486.
121. Berdy GJ, Abelson MB, Smith LM, George MA. Preservative-free artifical tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol. 1992;110:528-532.
122. Pissella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res. 2000;32:3-8.
123. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85-94.
124. Gasset AR, Ishii Y, Kaufman HE, Miller T. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol. 1974;78:98-105.
125. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular Preservatives: Associated Risks and Newer Options. Cutan Ocul Toxicol. 2009; 28:93-103.
126. Grant R, Ajello M, Vlass E. Salt water or high tech? A look at two new rinsing solutions for contact lenses. Optician. 1996;212:38-41.
127. Dong JQ, Babusis DM, Welty DF, Acheampong AA, Tang-Liu D, Whitcup SM. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther. 2004;20:285-292.
128. Acheampong AA, Small D, Baumgarten VAL, Welty D, Tang-Liu D. Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther. 2002;18:325-337.
129. Cantor L, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin. 2008;24:2035-2043.
130. Zimmerman TJ, Kaufman HE. Timolol, a β-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;1:601-604.
131. Uusitalo H, Kahonen M, Ropo A, Turjanmaa V. The evaluation of efficacy and systemic side effects of topical antiglaucoma drugs: the benefits of improved drug formulation. J Glaucoma. 1999;8: 264-265.
132. Everitt DE, Avorn J. Systemic side effects of medications used to treat glaucoma. Ann Int Med. 1990;112:120-125.
133. Wolfhagen FHJ, Groen FC, Ouwendijk RJ. Severe nausea and vomiting with timolol eye drops. Lancet. 1998:352-373.
134. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from mucoadhesive niosomal ophthalmic drug delivery system,. Int J Pharm. 2005;290:155-159.
135. Alonso MJ, Sanchez A. The potential of chitosan in ocular drug delivery. J Pharm Pharmacol. 2003;55:1451-1463.
136. Higashiyama M, Inada K, Ohtori A, Tojo K. Improvement of the ocular availability of timolol by sorbic acid. Int J Pharmaceut. 2004;272:91-98.
137. Akafo SK, Thompson JR, Rosenthal AR. A crossover trial comparing once-daily levobunolol with once- and twice-daily timolol. Eur J Ophthalmol. 1995;5:172-176.
138. Ikeda H, Sato M, Tsukamoto H, Sato E, Unei H, Kimura Y, Mishima H, Kihira K. Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions. Yakugaku Zasshi. 2001;121:799-806.
139. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26 233-236.
140. Baklayan GA, Collins EC, Thetford T, Soriano A, Song CK, Han J. Evaluation of aqueous humor concentrations of Istalol® and Betimol® following a single ocular instillation in rabbit eyes. J Ocul Pharmacol Ther. 2008;24:507-512.
141. Nordmann J, Mertz B, Yannoulis N, Schwenninger C, Kapik B, Shams N. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension: 6 month data. Am J Ophthalmol. 2002;133:1-10.
142. Serle JB. Brimonidine Study Group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol. 1996;41(Suppl 1):S39-S47.
143. Yarangumeli A, Kural G. Are there any benefits of Betoptic S (betaxolol HCl ophthalmic suspension) over other beta-blockers in the treatment of glaucoma? Expert Opin Pharmacother. 2004;5:1071-1081.
144. Jani R, Gan O, Ali Y, Rodstrom R, Hancock S. Ion Exchange Resins for Ophthalmic Delivery. J Ocul Pharmacol Ther. 1994;10:57-67.
145. Marchal-Heussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Colloidal drug delivery systems for the eye: a comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate polylactic-co-lycolic acid, poly-e-caprolactone. STP Pharm Sci. 1992;2:98-104.
146. Duff GR, Newcombe RG. The twelve hour control of intraocular pressure on carteolol 2% twice daily. Br J Ophthalmol. 1988;72:890-891.
147. Fraunfelder FT, Meyer SM. Sexual dysfunction secondary to topical ophthalmic timolol. JAMA. 1985;253:3092-3093.
148. Ischikawa Y, Kiuchi Y, Takamatsu M, Mashima H. Effects of beta adrenergic blockers on retinal circulation. Nippon Ganka Gakkai Zasshi. 1996;100:798-802.
149. Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly (e-eaprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res. 1993;10:386-390.
150. Sakurai M, Araie M, Oshika T, Mori M, Shoji N, Masuda K. Effects of topical application of UF 021, a novel prostaglandin-related compound, on aqueous humor dynamics in rabbit. Jpn J Ophthalmol. 1993;37:252-258.
151. Taniguchi T, Haque MS, Sugiyama K, Hori N, Kitazawa Y. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits. J Ocul Pharmacol Ther. 1996;12:489-498.
152. Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol. 1993;37:514-525.
153. Yamamoto T, Kitazawa Y, Azuma I, Masuda K. Clinical evaluation of UF-021 (Rescula isopropyl unoprostone). Surv Ophthalmol. 1997;41:99-103.
154. Alm A, Stjernschantz J. For the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening and morning: a comparison with timolol. Ophthalmol. 1995;102:1743-1752.
155. Camras CB. For the United States. Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmol. 1996;103:138-147.
156. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week study. Arch Ophthalmol. 1996;114:929-932.
157. Watson P, Stjernschantz J. For the Latanoprost Study Group. A six-month, randomized, doublemasked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmol. 1996;103:126-137.
158. Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in subjects with ocular hypertension. Ophthalmol. 2001;108:1439-1444.
159. Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. Bimatoprost Circadian IOP Study Group. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49:26-35.
160. Novack GD, O'Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002;50:956-962.
161. Chiba T, Kashiwagi K, Ishiiima K. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol 2004;48.
162. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124:544-547.
163. Noecker RJ. The management of glaucoma and intraocular hypertension: current approaches and recent advances. Ther Clin Risk Manag. 2006;2:193-206.
164. Cohen JS, Gross RL, Cheetham JK, Vandenburgh AM, Bernstein P, Whitcup SM. Two-year doublemasked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49:45-52.
165. Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
166. Gandolfi S, Simmons ST, Sturm R, Chen K, Van Denburgh AM. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110-121.
167. Noecker RJ, Dirks MS, Choplin N, Bernstein P, Batoosingh AL, Whitcup SM. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55-63.
168. Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
169. Martinez A, Sanchez M. Intraocular pressure-lowering effect of dorzolamide/timolol fixed combination in patients with glaucoma who were unresponsive to prostaglandin analogs/prostamides. Curr Med Res Opin. 2007;23:595-599.
170. Gandolfi SA, Cimino L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmol. 2003;110:609-614.
171. Williams RD. Efficacy of bimatoprost in glaucoma and ocular hypertension unresponsive to latanoprost. Adv Ther. 2002;19:175-228.
172. Sonty S, Donthamsetti V, Vangipuram G, Ahmad A. Long-term IOP lowering with bimatoprost in openangle glaucoma patients poorly responsive to latanoprost. J Ocul Pharmacol Ther. 2008;24:517-520.
173. Eisenberg DL, Toris CB, Camras C. Bimatoprost and travoprost a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47:105-115.
174. Boger WP, 3rd, Steinert RF, Puliafito CA, Pavan-Langston D. Clinical trial comparing timolol ophthalmic solution to pilocarpine in open-angle glaucoma. Am J Ophthalmol. 1978;86:8-18.
175. Uusitalo RJ, Palkama A. Long-term evaluation of timolol. Acta Ophthalmol. 1989;67:573-581.
176. Hartenbaum D. The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with openangle glaucoma and ocular hypertension. Clin Ther. 1996;18:460-465.
177. Zimmerman TJ, Canale P. Timolol-further observations. Ophthalmol. 1979;86:166-169.
178. Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N, Avorn J. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711-716.
179. Weinreb RN. Compliance with medical treatment in glaucoma. J Glaucoma. 1992;1:134-136.
180. Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci. 1974;63:333-338.
181. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80-86.
182. Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed-combination timolol/ dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther. 2003;19:93-96.
183. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target. 2010;18:292-302.
184. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21:337-348.
185. Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in openangle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004;5:909-921.
186. Shin DH, Feldman RM, Sheu WP. Fixed Combination Latanoprost/Timolol Study Group. Efficacy and safety of the fixed combination latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmol 2004;111:276-282.
187. Garcia-Sanchez J, Rouland JE, Spiegel D, Pajic B, Cunliffe I, Traverso C, Landry J. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elvevated intraocular pressure: a six month, evaluator masked, multicentre study in Europe. Br J Ophthalmol. 2004;88:877-883.
188. Teus MA, Miglior S, Laganovska G, Volksone L, Romanowska-Dixon B, Gos R, Hollo G. Efficacy and safety of ravoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2009;3:629-636.
189. Bi F, Liu N, Fan D. Small interfering RNA: a new tool for gene therapy. Curr Gene Ther. 2003;3:411-417.
190. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell. 2001;107:309-321.
191. Zamore PD, Tuschl T, Sharp PA. RNAi: double- stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell. 2000;101:25-33.
192. Kim BS, O.V. S, Reedy MV, J. M, Lun Y, Gan L, R.S. S, Tomarev SI, John SW, R.L. J. Targeted disruption of the myocilin gene (Myoc) suggests that human glaucoma-causing mutations are gain of function. Mol Cell Biol. 2001;21:7707-7713.
193. Comes N, Borras T. Functional delivery of synthetic naked siRNA to the human trabecular meshwork in perfused organ cultures. Mol Vis. 2007;13:1363-1374.
194. Li M, Xu J, Chen X, Sun X. RNA interference as a gene silencing therapy for mutant MYOC protein in primary open angle glaucoma. Diag Pathol. 2009;4:46.
195. Chatterton JE, Clark AF, Bingaman DP, Wax MB, Timmers AM., RNAi-related inhibition of TNFa signaling pathway for treatment of glaucoma. United States Patent Application 20090035225, Published on 02/05/2009.
196. Wang WH, McNatt LG, Pang IH, Hellberg PE, Fingert JH, McCartney MD, Clark AF. Increased expression of serum amyloid a in glaucoma and its effect on intraocular pressure. Invest Ophthalmol Vis Sci. 2008;49:1916-1923.
197. Clark AF, Wang WH, McNatt L: RNAi mediated inhibition of frizzled related protein-1 for treatment of glaucoma. United States Patent Application 20060223773, Published on 10/05/2006.
198. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today. 2006;11:67-73.
199. Oliveira S, Hogset A, Storm G, Schiffelers RM. Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo. Curr Pharm Des. 2008;14:3686-3697.
200. Khurana B, Goyal AK, Budhiraja A, Arora D, Vyas SP. Current Gene Therapy, siRNA delivery using nanocarriers-an efficient tool for gene silencing. Curr Gene Ther. 2010;10:1-17.
201. http://www.prnewswire.com/news-releases/quark-pharmaceuticals-qpi-1007-exhibits-neuroprotective-effects-in-glaucoma-model-97297494.html. Accessed on 20 August, 2010.
202. http://www.genomeweb.com/rnai/spains-sylentis-looks-move-sirna-based-glaucoma-drug-phase-iyear. Accessed on 28 July, 2010.
203. Diestelhorst M, Krieglstein GK. The intraocular pressure response of human atrial natriuretic factor in glaucoma. Int Ophthalmol. 1989;13:99-101.
204. Widmer F, Gauri KK, Aasmul-olsen S: Peptide derivative, pharmaceutical preparation containing it and method for treatment of glaucoma. United States Patent 5411942, Published on 05/02/1995.
205. Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci 2009;14:1-18.
206. Colasanti M, Suzuki H. The dual personality of NO. Trends Pharmacol Sci. 2000;21:249-252.
207. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci. 1995;36:1765-1773.
208. Polak K, Luksch A, Berisha F, Fuchsjaeger-Mayrl G, Dallinger S, Schmetterer L. Altered nitric oxide system in patients with open-angle glaucoma. Arch Ophthalmol. 2007;125:494-498.
209. Kotikoski H, Alajuuma P, Moilanen E, Salmenpera P, Oksala O, Laippala P, Vapaatalo H. Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP. J Ocular Pharmacol Ther. 2002;18:11-23.
210. Feelisch M. The use of nitric oxide donors in pharmacological studies. Naunyn-Schmiedeberg's Arch Pharmacol. 1998;358:113-122.
211. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol. 1999;34:879-886.
212. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43:109-142.
213. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis. 1996;55:7-20.
214. Nathanson JA. Nitric oxide and nitrovasodilators in the eye: implications for ocular physiology and glaucoma. J Glaucoma. 1993;2:206-210.
215. Sugrue MF. New approaches to antiglaucoma therapy. J Med Chem. 1997;40:2793-809.
216. Behar-Cohen FF, Goureau O, D'Hermies F, Courtois Y. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye. Invest Ophthalmol Vis Sci. 1996;37:1711-1715.
217. Nathanson JA. Nitrovasodilators as a new class of ocular hypotensive agents. J Pharm Exp Ther. 1992;260:956-965.
218. Orihashi M, Shima Y, Tsuneki H, Kimura I. Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits. Biol Pharm Bull. 2005;28:65-68.
219. Borghi V, Bastia E, Guzzetta M, Chiroli V, Toris CB, Batugo MR, Carreiro ST, Chong WKM, Gale DC, Kucera DJ, Jia L, Prasanna G, Ongini E, Krauss AHP, Impagnatiello F. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma. J Ocular Pharmacol Ther. 2010;26:125-131.
220. Russell P, Johnson DH. Enzymes protective of oxidative damage present in all decades of life in the trabecular meshwork, as detected by two-dimensional gel electrophoresis protein maps. J Glaucoma. 1996;5:317-324.
221. Saccà SC, Izzotti A, Rossi P, Traverso C. Glaucomatous outflow pathway and oxidative stress. Exp Eye Res. 2007;84:389-399.
222. Ueda J, Wentz-Hunter K, Yue BY. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest Ophthalmol Vis Sci. 2002;43:1068-1076.
223. Zhou L, Li Y, Yue BY. Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. J Cell Physiol. 1999;180:182-189.
224. Rose RC, Richer SP, Bode AM. Ocular oxidants and antioxidant protection. Proc Soc Exp Biol Med. 1998;217:397-407.
225. Spector A, Garner WH. Hydrogen peroxide and human cataract. Exp Eye Res. 1981;33:673-681.
226. Li AF, Tane N, Roy S. Fibronectin overexpression inhibits trabecular meshwork cell monolayer permeability. Mol Vis. 2004;10:750-757.
227. Wentz-Hunter K, Shen X, Okazaki K, Tanihara H, Yue BY. Overexpression of myocilin in cultured human trabecular meshwork cells. Exp Cell Res. 2004;297:39-48.
228. Eckert A, Keil U, S. K, Schindowski K, Leutner S, Leutz S, Miller WE. Effects of EGb 761 Ginkgo biloba extract on mitochondrial function and oxidative stress. Pharmacopsychiatry. 2003;36:S15-S23.
229. Eckert A, Keil U, Scherping I, Hauptmann S, Muller WE. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann NY Acad Sci. 2005;1056:474-485.
230. Quaranta L, Bettelli S, Uva MG, Semeraro F, Turano R, Gandolfo E. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmol. 2003;110:359-362.
231. Ritch R. Potential role for Ginkgo biloba extract in the treatment of glaucoma. Med Hypotheses. 2000;54:221-235.
232. Kim AR, Zou Y, Kim HS, Choi JS, Chang GY, Kim YJ, Chung HY. Selective peroxynitrite scavenging activity of 3-methyl-1,2-cyclopentanedione from coffee extract. J Pharm Pharmacol. 2002;54:1385-1392.
233. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006;231:113-122.
234. Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, Kwak HK, Milbury P, Paul SM, Blumberg J, Mietus-Snyder ML. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr. 2004;23:197-204.
235. Grassi D, Necozione S, Lippi C, Croce G, Valeri L, Pasqualetti P, Desideri G, Blumberg JB, Ferri C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension. 2005;46:398-405.
236. Karim M, McCormick K, Kappagoda CT. Effects of cocoa extracts on endothelium-dependent relaxation. J Nutr. 2000;130:2105S-218S.
237. Filina AA, Davydova NG, Endrikhovskii SN, Shamshinova AM. Lipoic acid as a means of metabolic therapy of open-angle glaucoma. Vestn Oftalmol. 1995;111:6-8.
238. Asregadoo ER. Blood levels of thiamine and ascorbic acid in chronic open-angle glaucoma. Ann Ophthalmol. 1979;11:1095-1100.
239. Kishimoto M, Nakamori F. Effect of vitamin B12 on reduced visual function due to glaucoma. Nippon Ganka Kiyo. 1965;16:291-7.
240. Lin Y, Desbois A, Jiang S, Hou ST. Group B vitamins protect murine cerebellar granule cells from glutamate/NMDA toxicity. Neuroreport. 2004;15:2241-2244.
241. Ullegaddi R, Powers HJ, Gariballa SE. Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial. J Parenter Enteral Nutr. 2006;30:108-114.
242. van der Kuy PH, Merkus FW, Lohman JJ, ter Berg JW, Hooymans PM. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia. 2002;22:513-519.
243. Babizhayev MA, Burke L, Micans P, Richer SP. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: Glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. Clin Interv Aging. 2009;4:31-50.
244. Babizhayev MA, Seguin MC, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem J. 1994;304:509-516.
245. Babizhayev MA, Yermakova VN, Sakina NL, Evstigneeva RP, Rozhkova EA, Zheltukhina GA. N alpha-acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin Chim Acta. 1996;254:1-21.
246. Ermakova VN, Babizhaev MA, Ya A. Effect of L-carnosine on the intraocular pressure. Bunin Bull Exp Biol Med. 1988;105:540-542.